» Articles » PMID: 20217603

LHRH-targeted Nanoparticles for Cancer Therapeutics

Overview
Specialty Molecular Biology
Date 2010 Mar 11
PMID 20217603
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Synthesis and evaluation of a novel cancer cell's receptor-targeted internally quaternized and surface neutral poly(amidoamine) (PAMAM) generation four dendrimer as well as PAMAM-paclitaxel conjugate are described. The advantages of developed nanocarriers include but are not limited to (1) internal cationic charges for the complexation with small interfering RNA or antisense oligonucleotides and their protection from the degradation in systemic circulation; (2) neutral-modified surface for low cytotoxicity of empty unloaded dendrimers; (3) efficient internalization by cancer cells; and (4) preferential accumulation in the tumor and the prevention of adverse side effects of chemotherapy.

Citing Articles

Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.

Garbuzenko O, Sapiezynski J, Girda E, Rodriguez-Rodriguez L, Minko T Small. 2024; 20(41):e2307462.

PMID: 38342698 PMC: 11316847. DOI: 10.1002/smll.202307462.


The landscape of nanoparticle-based siRNA delivery and therapeutic development.

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y Mol Ther. 2024; 32(2):284-312.

PMID: 38204162 PMC: 10861989. DOI: 10.1016/j.ymthe.2024.01.005.


Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer.

Vishwasrao H, Master A, Seo Y, Liu X, Pothayee N, Zhou Z Chem Mater. 2023; 28(9):3024-3040.

PMID: 37405207 PMC: 10317193. DOI: 10.1021/acs.chemmater.6b00197.


Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers.

Garrido M, Hernandez A, Vega M, Araya E, Romero C Front Endocrinol (Lausanne). 2023; 14:1143261.

PMID: 37056674 PMC: 10086188. DOI: 10.3389/fendo.2023.1143261.


Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations.

Majumder J, Minko T Pharmaceutics. 2021; 13(7).

PMID: 34371754 PMC: 8309189. DOI: 10.3390/pharmaceutics13071063.